Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). - Innovaderm Research

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

Test

Post navigation

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

Dermatology Clinic
3530 Saint-Laurent boulevard
Suite 400
Montreal, QC, H2X 2V1, Canada

© Innovaderm 2025. All rights reserved.

Facebook-f Instagram Linkedin